Journal profile · Psychiatry
Neuropsychopharmacology
ISSN 0893-133X · eISSN 1740-634X · Springer Nature · ENGLAND · Monthly · Founded 1993
Neuropsychopharmacology: CAS Zone 2 · Medicine (2025 upgraded edition, Top journal); impact factor 7.53; hybrid open access; APC about USD 5,290; median 116 days to acceptance (86 articles, last 24 months); community-reported acceptance: about 28.75%; 260 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Neuropsychopharmacology is published by Springer Nature and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Neurotransmitter Receptor Influence on Behavior, Neuroscience and Neuropharmacology Research and Receptor Mechanisms and Signaling, together about 37.6% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Neuropsychopharmacology is an international scientific journal and the official publication of the American College of Neuropsychopharmacology (ACNP). This journal focuses on clinical and basic science contributions that advance our understanding of the brain and behaviour, especially as related to the molecular, cellular, physiological and psychological properties of agents acting within the central nervous system and the identification of the new molecular targets for the development of the next generation of drugs. While original reports are preferred, mini-reviews and perspectives are invited by the editorial office. In view of the interdisciplinary nature of the field, particular emphasis is placed on: studies that advance the biological bases of normal and pathological behavior the nature, etiology and pathophysiology of neuropsychiatric disorders biologically relevant aspects of the epidemiology, diagnosis, and treatment of these disorders and the basic mechanisms by which psychopharmacological agents exert their effect
From the journal's Aims & Scope
Research area (LetPub): Psychiatry
Main research topics OpenAlex counts of recent articles; shares are approximate
- Neurotransmitter Receptor Influence on BehaviorNeuroscience17.1%
- Neuroscience and Neuropharmacology ResearchNeuroscience12.9%
- Receptor Mechanisms and SignalingBiochemistry, Genetics and Molecular Biology7.6%
- Stress Responses and CortisolNeuroscience7.5%
- Memory and Neural MechanismsNeuroscience5.3%
- Tryptophan and brain disordersNeuroscience5%
- Functional Brain Connectivity StudiesNeuroscience5%
- Neuroendocrine regulation and behaviorPsychology4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 1 |
| Minor | Neurosciences | Zone 2 |
| Minor | Psychiatry | Zone 2 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Neurosciences | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 1 |
| Minor | Psychiatry | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Neurosciences | Zone 1 |
| Minor | Pharmacology & Pharmacy | Zone 1 |
| Minor | Psychiatry | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEPubMedEmbasePsycINFOCASCAB AbstractsCurrent ContentsPublisher website
Other: Google Scholar, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Crossref, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 7.53LetPub ·
- Impact factor (publisher) 2025
- 7.6Publisher website ·
- 5-year impact factor (publisher) 2025
- 9.1Publisher website ·
- CiteScore 2026-06
- 15.7LetPub ·
- SJR 2026-06
- 2.99LetPub ·
- SJR (publisher) 2025
- 2.99Publisher website ·
- SNIP 2026-06
- 2.34LetPub ·
- SNIP (publisher) 2025
- 2.34Publisher website ·
- h-index
- 204LetPub ·
- h-index
- 309OpenAlex ·
- i10-index
- 6,780OpenAlex ·
- 2-year mean citedness
- 4.87OpenAlex ·
- Self-citation rate
- 2.6%LetPub ·
- Share of gold OA articles
- 50.27%LetPub ·
Volume
- Articles per year
- 197LetPub ·
- Downloads per year (publisher) 2025
- 10,343,688Publisher website ·
Articles by year OpenAlex count · 8,999 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 263 | 225 | 207 |
| 2025 | 260 | 226 | 1,027 |
| 2024 | 262 | 262 | 2,588 |
| 2023 | 301 | 260 | 5,515 |
| 2022 | 271 | 271 | 7,148 |
| 2021 | 322 | 321 | 14,454 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
116 daysMedian, submission to acceptance · P25–P75 81 days – 139 days
- Acceptance to online
- median 16 days (86 articles)
- Submission to online
- median 138 days
- Sample
- 86 articles with submission and acceptance dates (573 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 2 monthsLetPub ·
- Average acceptance (community reports)
- 28.75%LetPub ·
- Submission to first decision
- 2 daysPublisher website ·
- Submission to acceptance
- 102 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 5,290 / EUR 4,190 / GBP 3,590 | — | — | |
| Publisher website | GBP 1,750 / USD 2,575 / EUR 2,040 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted6
- articleArticleOpen Access23 Jul 2026Length not stated
- commentComment29 Jun 2026Length not stated
- hot topicsHot Topics11 Sept 2026Length not stated
- in memoriamIn Memoriam08 Jul 2026Length not stated
- npp briefsNPP Briefs14 Sept 2026Length not stated
- research highlightResearch HighlightOpen Access23 Jul 2026Length not stated
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Nature
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Monthly
- Founded
- 1993
- ISSN
- 0893-133X
- Electronic ISSN
- 1740-634X
- Society / sponsor
- American College of Neuropsychopharmacology 10
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Neuropsychopharmacology
What CAS zone is Neuropsychopharmacology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Neuropsychopharmacology is in Zone 2 of Medicine, and in Zone 1 of the minor category Pharmacology & Pharmacy / Neurosciences / Psychiatry; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Neuropsychopharmacology?
The latest impact factor listed by LetPub is 7.53; CiteScore 15.7, h-index 309.
How long does peer review take at Neuropsychopharmacology?
Based on the dates recorded on 86 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 116 days (interquartile range 81–139 days); authors report an average review time of about 2 months; the community-reported acceptance is “about 28.75%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Neuropsychopharmacology?
According to LetPub and DOAJ records, Neuropsychopharmacology is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, PubMed, Embase, PsycINFO, CAS, CAB Abstracts and Current Contents; that list has not been checked against each database.
Is Neuropsychopharmacology open access, and what is the APC?
Neuropsychopharmacology is a hybrid journal. For open-access publication: APC about USD 5,290.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .